Medicare Enrolled

Dr. Mukesh Kumar Delvadiya, M.D.

Internal Medicine · Plano, TX
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
6300 W. PARKER ROAD, SUITE 123, MOB II, Plano, TX 75093
9723982899
In practice since 2008 (17 years)
NPI: 1003070004 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Delvadiya from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Delvadiya? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Delvadiya

Dr. Mukesh Kumar Delvadiya is an internal medicine specialist in Plano, TX, with 17 years of NPI registration. Based on federal Medicare data, Dr. Delvadiya performed 21,378 Medicare services across 1,398 unique beneficiaries.

Between the years covered by Open Payments, Dr. Delvadiya received a total of $6,924 from 66 pharmaceutical and/or device companies across 344 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Delvadiya is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 17 years in practice ▲ Top 2% volume in TX $6,924 industry payments

Medicare Practice Summary

Medicare Utilization ↗
21,378
Medicare services
Top 2% in TX for internal medicine
1,398
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,258 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Iron sucrose injection (Venofer) 8,800 $0 $2
Anti-nausea injection (fosaprepitant) 6,450 $0 $5
Dexamethasone injection (steroid) 1,878 $0 $1
Complete blood count (CBC) with differential 635 $8 $36
Blood draw (venipuncture) 629 $8 $20
Anti-nausea injection (Aloxi/palonosetron) 430 $1 $114
Office visit, established patient, complex (40-54 min) 371 $133 $496
Office visit, established patient (30-39 min) 234 $90 $368
Comprehensive metabolic blood panel 199 $10 $64
Injection of additional new drug or substance into vein 179 $12 $108
Magnesium level test 165 $7 $29
Phosphate level test 162 $5 $24
Administration of chemotherapy into vein, 1 hour or less 153 $98 $707
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less 110 $22 $157
Ferritin level test (iron stores) 93 $13 $60
Iron level test 93 $6 $27
Iron binding capacity test 93 $8 $35
Administration of additional new drug or substance into vein, 1 hour or less 90 $49 $344
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less 72 $46 $313
Carcinoembryonic antigen (cea) protein level 64 $19 $99
Hospital follow-up visit, high complexity 60 $91 $357
New patient office visit, complex (60-74 min) 53 $153 $709
Microscopic examination for white blood cells with manual cell count 47 $4 $22
Complete blood count (CBC), automated 47 $6 $34
Initial hospital admission, high complexity 41 $133 $694
Drug injection, under skin or into muscle 40 $11 $96
Office visit, established patient (20-29 min) 34 $67 $250
Administration of chemotherapy into vein, each additional hour 29 $21 $161
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries 27 $91 $657
New patient office visit (45-59 min) 26 $119 $565
Nuclear medicine study from skull base to mid-thigh with ct scan 22 $1,113 $4,802
Lactate dehydrogenase (enzyme) level 22 $6 $31
Manual urinalysis test with examination using microscope, non-automated 17 $4 $26
Red blood count, automated test 13 $4 $23
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.9% high complexity
84.1% medium
15.0% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$6,924
Total received (2018-2024)
Avg $989/year across 7 years
Top 12% in TX for internal medicine
66
Companies
344
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,737 (82.9%)
Other
Charitable contributions, space rental, and other categories
$722 (10.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$465 (6.7%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,309
2023
$1,430
2022
$1,114
2021
$133
2020
$248
2019
$235
2018
$1,454

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,265
Celgene Corporation
$490
Janssen Biotech, Inc.
$395
PFIZER INC.
$382
Incyte Corporation
$374
E.R. Squibb & Sons, L.L.C.
$293
AstraZeneca Pharmaceuticals LP
$288
Amgen Inc.
$218
GENZYME CORPORATION
$191
Merck Sharp & Dohme LLC
$181
Rigel Pharmaceuticals, Inc.
$158
GlaxoSmithKline, LLC.
$153
SOBI, INC
$132
Astellas Pharma US Inc
$127
Daiichi Sankyo Inc.
$126
Eisai Inc.
$112
Gilead Sciences, Inc.
$109
Epizyme, Inc.,
$99
PharmaEssentia USA Corporation
$96
Genentech USA, Inc.
$92
TESARO, Inc.
$85
Seagen Inc.
$74
Karyopharm Therapeutics Inc.
$68
ABBVIE INC.
$64
Merck Sharp & Dohme Corporation
$62
Takeda Pharmaceuticals U.S.A., Inc.
$60
EISAI INC.
$57
BeiGene USA, Inc.
$57
Adaptive Biotechnologies Corporation
$56
Pharmacyclics LLC, An AbbVie Company
$56
GE HealthCare
$54
INSYS Therapeutics Inc
$50
ARRAY BIOPHARMA INC
$49
MEDIVATION FIELD SOLUTIONS LLC
$48
Ipsen Biopharmaceuticals, Inc
$46
Stemline Therapeutics Inc.
$42
PUMA BIOTECHNOLOGY, INC.
$40
Bayer HealthCare Pharmaceuticals Inc.
$39
Lexicon Pharmaceuticals, Inc.
$37
Myriad Genetic Laboratories, Inc.
$35
Sirtex Medical Inc
$33
Janssen Scientific Affairs, LLC
$31
Taiho Oncology, Inc.
$29
Kite Pharma, Inc.
$28
Tempus AI, Inc
$26
Lilly USA, LLC
$25
Sobi, Inc
$25
AVEO Pharmaceuticals, Inc.
$25
CTI BioPharma Corp.
$24
Regeneron Healthcare Solutions, Inc.
$24
SpringWorks Therapeutics, Inc.
$23
AbbVie, Inc.
$22
EMD Serono, Inc.
$21
Alexion Pharmaceuticals, Inc.
$21
Bayer Healthcare Pharmaceuticals Inc.
$20
Exelixis Inc.
$20
ADC Therapeutics America, Inc.
$20
Blueprint Medicines Corporation
$20
Verastem, Inc.
$18
SANOFI-AVENTIS U.S. LLC
$18
Pharmacosmos Therapeutics Inc.
$18
Alnylam Pharmaceuticals Inc.
$17
JAZZ PHARMACEUTICALS INC.
$17
Foundation Medicine, Inc.
$16
Boehringer Ingelheim Pharmaceuticals, Inc.
$13
Mylan Institutional Inc.
$12
Top 3 companies account for 31.0% of total payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AFINITOR · ALIMTA · AYVAKIT · Abraxane · BAVENCIO · BESREMI · BLENREP · BOSULIF · BRUKINSA · CABLIVI · CALQUENCE · CARVYKTI · CHANTIX · CREON · Cabometyx · Copiktra · DARZALEX · DOPTELET · Doptelet · ELITEK · ELREXFIO · EMEND · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · Enhertu · FOTIVDA · Fulphila · GAZYVA · GILOTRIF · GIVLAARI · HEMLIBRA · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JADENU · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · NERLYNX · NINLARO · Neulasta · Nexavar · Nplate · OGSIVEO · OJJAARA · OPDIVO · OPDUALAG · OXBRYTA · Orserdu · PADCEV · PIQRAY · PLUVICTO · PRECISETUMOR · PROMACTA · Padcev · Pomalyst · PreciseTumor · REBLOZYL · RYBREVANT · Revlimid · Rezlidhia · SARCLISA · SHINGRIX · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SUTENT · SYNDROS · Somatuline Depot · Stivarga · TAGRISSO · TAZVERIK · TECENTRIQ · TECVAYLI · TUKYSA · Tavalisse · Trodelvy · VENCLEXTA · VERZENIO · VONVENDI · Venclexta · Vonjo · XALKORI · XPOVIO · XT CDX · XTANDI · Xermelo · Xtandi · ZEJULA · ZEPZELCA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (83%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $32 per 100 Medicare services performed
Looking for an internal medicine specialist in Plano?
Compare internal medicine physicians in the Plano area by procedure volume, costs, and industry payment transparency.
Browse internal medicine physicians nearby

Geographic Context

Internal medicine physicians within 10 mi
2,127
Per 100K population
190.5
County median income
$117,588
Nearest hospital
TEXAS HEALTH PRESBYTERIAN HOSPITAL PLANO
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Delvadiya is a mixed practice specialist, with above-average Medicare volume (top 2% in TX), with low-engagement industry engagement in the top 12% of TX peers, with 17 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Delvadiya experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Delvadiya performed 8,800 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Delvadiya receive payments from pharmaceutical companies?
Yes. Dr. Delvadiya received a total of $6,924 from 66 companies across 344 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Delvadiya's costs compare to other internal medicine physicians in Plano?
Dr. Delvadiya's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Delvadiya) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →